Durvalumab/Tremelimumab Combo Could Expand Frontline Options in Advanced HCC
July 1st 2020
Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.